Peptide inhibitors of HIV entry

Details Peptide inhibitors of HIV entry Peptide inhibitors of HIV entry

2007-06-05

2007-06-05

Parkin, Jeffrey S. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

Reexamination Certificate

active

10395817

ABSTRACT:
Described herein are chimeric peptides comprising a soluble trimeric coiled-coil and all or a portion of the N-peptide region of HIV gp41. These molecules are stable, trimeric coiled-coils that inhibit HIV entry into cells, such as human cells. Such peptides can be further assessed to demonstrate their ability to serve as potent anti-HIV therapeutic molecules and thus, as therapeutic molecules or drugs.

REFERENCES:
patent: 5444044 (1995-08-01), Jiang et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5656480 (1997-08-01), Wild et al.
patent: 5780221 (1998-07-01), Schumacher et al.
patent: 5840843 (1998-11-01), Jiang et al.
patent: 6150088 (2000-11-01), Chan et al.
patent: 6506554 (2003-01-01), Chan et al.
patent: 6747126 (2004-06-01), Eckert et al.
patent: 6818740 (2004-11-01), Eckert et al.
patent: 7053179 (2006-05-01), Root et al.
patent: 2001/0047080 (2001-11-01), Root et al.
patent: 2002/0077284 (2002-06-01), Eckert et al.
patent: 2003/0082525 (2003-05-01), Root et al.
patent: 2003/0099935 (2003-05-01), Chan et al.
patent: 2005/0053917 (2005-03-01), Chan et al.
patent: 2005/0221294 (2005-10-01), Eckert et al.
patent: 2006/0014139 (2006-01-01), Root et al.
patent: WO 94/02505 (1994-02-01), None
patent: WO 96/40191 (1996-12-01), None
patent: WO 98/32848 (1998-07-01), None
patent: WO 00/06599 (2000-02-01), None
patent: WO 00/40616 (2000-07-01), None
patent: WO 01/03723 (2001-01-01), None
patent: WO 01/44286 (2001-06-01), None
Cao, J., et al., 1993, Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein, J. Virol. 67(5):2747-2755.
Moschella, F., et al., 2003, Administration of different antigenic forms of altered peptide ligands derived from HIV-1 RTase influences their effects on T helper cell activation, Hum. Immunol. 64:1-8.
Manchester, M., et al., 1994, Identification of temperature-sensitive mutants of the human immunodeficiency virus type 1 protease through saturation mutagenesis, J. Biol. Chem. 269(10):7689-7695.
Chan, D.C. and Kim, P.S., “HIV Entry and Its Inhibition,”Cell 93:681-684 (1998).
Jiang, S., et al., “A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a comformation-specific monoclonal antibody,”J. Virol. Methods 80(1):85-96 (1999).
Kilby, J.M., et al., “Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry,”Nature Medicine 4(11):1302-1307 (1998).
Richman, D.D., “Nailing down another HIV target,”Nature Medicine,4(11):1232-1233 (1998).
Bahbouhi, B., et al., “Effects of L-and D-REKR Amino Acid-Containing Peptides on HIV and SIV Envelope Glycoprotein Precursor Maturation and HIV and SIV Replication,”Biochem. J. 366(Pt. 3):863-872 (2002).
Meng, Elaine C., et al., “Automated Docking with Grid-Based Energy Evaluation,”Journal of Computational Chemistry,13(4):505-524 (1992).
Kuntz, Irwin D., “Structure-Based Strategies for Drug Design and Discovery,”Science,257:1078-1082 (1992).
Gallaher, William R., et al., “A General Model for the Transmembrane Proteins of HIV and Other Retroviruses,”Aids Research and Human Retroviruses,5(4):431-440 (1989).
Chambers, Philip, et al., “Heptad Repeat Sequences are Located Adjacent to Hydrophobic Regions in Several Types of Virus Fusion Glycoproteins,”Journal of General Virology,71:3075-3080 (1990).
Baum, Rudy, “Virus-cell Fusion Targeted for Drug Development,”C&EN(May 13, 1996).
Delwart, Eric L., et al., “Retroviral Envelope Glycoproteins Contain a ‘Leucine Zipper’-like Repeat,”AIDS Research and Human Retroviruses,6(6):703-706 (1990).
Li, Zhe, et al., “Anti-malarial Drug Development Using Models of Enzyme Structure,”Chemistry&Biology,1:31-37 (1994).
Blacklow, Stephen C., et al., “A Trimeric Subdomain of the Simian Immunodeficiency Virus Envelope Glycoprotein,”Biochemistry,34(46):14955-14962 (1995).
Lu, Min, et al., “A Trimeric Structural Domain of the HIV-1 transmembrane glycoprotein,”Nature Structural Biology,2(12):1-8 (1995).
Fass, Deborah and Kim, Peter S., “Dissection of a Retrovirus Envelope Protein Reveals Structural Similarity to Influenza Hemagglutinin,”Current Biology,5(12):1-7 (1995).
Ring, Christine S., et al., “Structure-based Inhibitor Design by Using Protein Models for the Development of Antiparasitic Agents,”Proc. Natl. Acad. Sci. USA,90:3583-3587 (1993).
Weissenhorn, W., et al., Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed inEscherichia coli, Proc. Natl. Acad. Sci. USA,94:6065-6069 (1997).
Judice, J. K., et al., Inhibition of HIV type 1 infectivity by constrained α-helical peptides: Implications for the viral fusion mechanism,Proc. Natl. Acad. Sci. USA,94:13426-13430 (1997).
Chan, D.C., et al., “Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target,”Proc. Natl. Sci. USA,95:15613-15617 (1998).
Eckert, Debra M., et al., “Inhibiting HIV-1 Entry: Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket,”Cell,99:103-115 (1999).
Blake, James and Li, Choh Hao, “Adrenocorticotropin. 47. Synthesis and Biological Activity of Adrenocorticotropic Peptides Modified at the Tryptophan Position,”J. Medicinal Chem. 18(4):423-426 (1975).
Borchardt, Allen et al., “Small Molecule-dependent genetic selection in stochastic nanodroplets as a means of detecting protein-ligand interactions on a large scale,”Chem.&Biol. 4(12):961-968 (1997).
Bullough, Per A., et al., “Structure of influenza haemagglutinin at the pH of membrane fusion,”Nature 371:37-43 (1994).
Caffrey, Michael et al., “Three-dimensional solution structure of the 44kDa ectodomain of SIV gp41,”EMBO J. 17(16):4572-4584 (1998).
Cao, Jie et al., “Effects of Amino Acid Changes in the Extracellular Domain of the Human Immunodeficiency Virus Type 1 gp41 Envelope Glycoprotein,”J. Virology 67(5):2747-2755 (1993).
Chabala, John C., “Solid-phase combinatorial chemistry and novel tagging methods for identifying leads,”Curr. Opin. Biotech. 6:632-639 (1995).
Chakrabartty, Avijit et al., “Aromatic Side-Chain Contribution to Far-Ultraviolet Circular Dichrosim of Helical Peptides and Its Effect on Measurement of Helix Propensities,”Biochemistry 32:5560-5565 (1993).
Chan, David C., et al., “Core Structure of gp41 from the HIV Envelope Glycoprotein,”Cell 89:263-273 (1997).
Chen, Yee-Hsiung et al., “Determination of the Helix and β Form of Proteins in Aqueous Solution by Circulation Dichrosism,”Biochemistry 13(16):3350-3359 (1974).
Chen, Benjamin K. et al., “Distinct Modes of Human Immunodeficiency Virus Type 1 Proviral Latency Revealed by Superinfection of Nonproductively Infected Cell Lines with Recombinant Luciferase-Encoding Viruses,”J. Virology 68(2):654-660 (1994).
Chen, Charlie L. et al., “One Bead-One Compound Combinatorial Peptide Library: Different Types of Screening,”Methods in Enzymology 267:211-219 (1996).
Chen, Chin-Ho et al., “A Molecular Clasp in the Human Immunodeficiency Virus (HIV) Type 1 TM Protein Determines the Anti-HIV Activity of gp41 Derivatives:Implication for Viral Fusion,”J. Virology 69(6):3771-3777 (1995).
Cole, James L. and Garsky, Victor M., “Thermodynamics of Peptide Inhibitor Binding to HIV-1 gp41,”Biochemistry 40:5633-5641 (2001).
Doering Don S. and Matsudaira, Paul, “Cysteine Scanning Mutagenesis at 40 of 76 Positions in Villin Headpiece Maps the F-Actin Binding Site and Structural Features of the Domain,”Biochemistry 35:12677-12685 (1996).
Dutch, Rebecca Ellis et al., “Paramyxovirus Fusion Protein: Characterization of the Core Trimer, a Rod-Shaped Complex with Helices in Anti-Parallel Or

Affiliated with

Also associated with

Rating

Peptide inhibitors of HIV entry does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide inhibitors of HIV entry, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide inhibitors of HIV entry will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3832664